Cover - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | ||
|---|---|---|---|
May 31, 2026 |
Sep. 28, 2026 |
Nov. 28, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | This Amendment No. 1 on Form 10-K/A (this “Amendment No. 1”) amends the Annual Report on Form 10-K for the fiscal year ended May 31, 2026 (the “2026 Annual Report”), originally filed by Biomerica, Inc. with the Securities and Exchange Commission (the “SEC”) on August 31, 2026. References throughout this Amendment No. 1 to “Biomerica, Inc.”, “Biomerica”, “we”, “us”, “our”, or the “Company” refer to Biomerica, Inc. and its subsidiaries, taken as a whole, unless the context otherwise indicates. We are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement for our 2026 Annual Meeting of stockholders (the “Annual Meeting”) within 120 days of the end of our fiscal year ended May 31, 2026. Accordingly, this Amendment No. 1 is being filed solely to: ● amend and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions, and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2026 Annual Report, in their entirety as set forth herein; and ● file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item 15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Because no financial statements are included in this Amendment No. 1, and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 or 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Additionally, new certifications under Section 906 of the Sarbanes-Oxley Act of 2002 are not being furnished with this Amendment No. 1. Except as set forth above, no other Items of our 2026 Annual Report have been amended or revised in this Amendment No. 1, and all such other Items shall be as set forth in such 2026 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2026 Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have the meanings given to them in the 2026 Annual Report. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | May 31, 2026 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2026 | ||
| Current Fiscal Year End Date | --05-31 | ||
| Entity File Number | 001-37863 | ||
| Entity Registrant Name | BIOMERICA, INC. | ||
| Entity Central Index Key | 0000073290 | ||
| Entity Tax Identification Number | 95-2645573 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 17571 Von Karman Avenue | ||
| Entity Address, City or Town | Irvine | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 92614 | ||
| City Area Code | (949) | ||
| Local Phone Number | 645-2111 | ||
| Title of 12(b) Security | Common Stock, par value $0.08 | ||
| Trading Symbol | BMRA | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 6.6 | ||
| Entity Common Stock, Shares Outstanding | 4,598,968 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Listing, Par Value Per Share | $ 0.08 |